Financhill
Sell
35

PPH Quote, Financials, Valuation and Earnings

Last price:
$88.25
Seasonality move :
-0.54%
Day range:
$87.57 - $88.53
52-week range:
$77.67 - $99.51
Dividend yield:
2.21%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
317K
Avg. volume:
443.8K
1-year change:
-4.95%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, VanEck Pharmaceutical ETF has -- downside to fair value with a price target of -- per share.

PPH vs. S&P 500

  • Over the past 5 trading days, VanEck Pharmaceutical ETF has overperformed the S&P 500 by 0.16% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • VanEck Pharmaceutical ETF does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • VanEck Pharmaceutical ETF has grown year-over-year revenues for 0 quarters straight. In the most recent quarter VanEck Pharmaceutical ETF reported revenues of --.

Earnings Growth

  • VanEck Pharmaceutical ETF has grown year-over-year earnings for 0 quarters straight. In the most recent quarter VanEck Pharmaceutical ETF reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-07-12 2024-07-12 2024-07-12
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -- -- -- -- --
EBITDA -- -- -- -- --
Diluted EPS -- -- -- -- --
Period Ending 2021-07-12 2022-07-12 2023-07-12 2024-07-12
Balance Sheet
Current Assets -- -- -- -- --
Total Assets -- -- -- -- --
Current Liabilities -- -- -- -- --
Total Liabilities -- -- -- -- --
Total Equity -- -- -- -- --
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-07-12 2024-07-12 2024-07-12
Cash Flow Statement
Cash Flow Operations -- -- -- -- --
Cash From Investing -- -- -- -- --
Cash From Financing -- -- -- -- --
Free Cash Flow -- -- -- -- --
PPH
Sector
Market Cap
--
--
Price % of 52-Week High
88.66%
--
Dividend Yield
2.21%
--
Shareholder Yield
--
--
1-Year Price Total Return
-4.95%
--
Beta (5-Year)
0.588
--
Dividend yield:
2.21%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $88.38
200-day SMA
Sell
Level $89.23
Bollinger Bands (100)
Sell
Level 85.17 - 91.87
Chaikin Money Flow
Buy
Level 229.1K
20-day SMA
Sell
Level $88.46
Relative Strength Index (RSI14)
Buy
Level 50.04
ADX Line
Buy
Level 20.07
Williams %R
Neutral
Level -54.3605
50-day SMA
Buy
Level $87.76
MACD (12, 26)
Buy
Level 19.71
25-day Aroon Oscillator
Sell
Level -24
On Balance Volume
Neutral
Level 1.1M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (5)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Stock Forecast FAQ

In the current month, PPH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PPH average analyst price target in the past 3 months is --.

  • Where Will VanEck Pharmaceutical ETF Stock Be In 1 Year?

    According to analysts, the consensus estimate is that VanEck Pharmaceutical ETF share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About VanEck Pharmaceutical ETF?

    Analysts are divided on their view about VanEck Pharmaceutical ETF share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that VanEck Pharmaceutical ETF is a Sell and believe this share price will rise from its current level to --.

  • What Is VanEck Pharmaceutical ETF's Price Target?

    The price target for VanEck Pharmaceutical ETF over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is PPH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for VanEck Pharmaceutical ETF is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of PPH?

    You can purchase shares of VanEck Pharmaceutical ETF via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase VanEck Pharmaceutical ETF shares.

  • What Is The VanEck Pharmaceutical ETF Share Price Today?

    VanEck Pharmaceutical ETF was last trading at $88.25 per share. This represents the most recent stock quote for VanEck Pharmaceutical ETF. Yesterday, VanEck Pharmaceutical ETF closed at $88.23 per share.

  • How To Buy VanEck Pharmaceutical ETF Stock Online?

    In order to purchase VanEck Pharmaceutical ETF stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Can FUBO Stock Double?
Can FUBO Stock Double?

TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…

Where Will CoreWeave Stock Be in 1 Year?
Where Will CoreWeave Stock Be in 1 Year?

When CoreWeave (NASDAQ: CRWV) slipped below its $40 IPO price…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock